Isentress 400mg

Raltegravir, marketed under the brand name Isentress, represents a groundbreaking advancement in the field of antiretroviral therapy for HIV/AIDS. As the first-in-class HIV integrase strand transfer inhibitor (INSTI), Raltegravir works by blocking the integration of the viral DNA into the host cell’s genome, thus preventing the replication of the virus. This unique mechanism of action makes Raltegravir highly effective, even against HIV strains resistant to other classes of antiretroviral drugs. Additionally, its favorable safety profile and minimal drug interactions render it a preferred choice in both treatment-naive and treatment-experienced patients. Furthermore, Raltegravir boasts a rapid onset of action and convenient once-daily dosing, offering patients improved adherence and tolerability compared to older antiretroviral agents. Its versatility and efficacy have solidified its position as a cornerstone of modern HIV therapy, contributing significantly to the management of HIV infection and improving the quality of life for millions of individuals worldwide.